Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
JNCI Cancer Spectrum|June 1, 2026
Emerging Role of Radiopharmaceutical Therapy in Oncology: Advances, Challenges, and Future DirectionsLaura Ordas, Sean Foster, Phuc Pham, et al.
Oncogene|September 15, 2005
Y-box factor YB1 controls p53 apoptotic functionCraig Homer, Deborah A Knight, Lynne Hananeia, et al.
Nucleic Acids Research|November 28, 2009
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probeAnnette Lasham, Mike Herbert, Natacha Coppieters 't Wallant, et al.
Cell Death & Disease|August 25, 2017
AKT2 suppresses pro-survival autophagy triggered by DNA double-strand breaks in colorectal cancer cellsNina Seiwert, Carina Neitzel, Svenja Stroh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 28, 2011
Selection of radioresistant tumor cells and presence of ALDH1 activity in vitroJulia Mihatsch, Mahmoud Toulany, Petra M Bareiss, et al.
Oncogene|May 14, 2003
Nuclear localization of Y-box factor YB1 requires wild-type p53You Fang Zhang, Craig Homer, Sara J Edwards, et al.
The Journal of Biological Chemistry|July 2, 2003
The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressorAnnette Lasham, Stephanie Moloney, Tracy Hale, et al.
Cancers|March 28, 2020
Accessing a New Dimension in TP53 Biology: Multiplex Long Amplicon Digital PCR to Specifically Detect and Quantitate Individual TP53 TranscriptsAnnette Lasham, Peter Tsai, Sandra J Fitzgerald, et al.
Pathology|April 9, 2024
Combining TP53 mutation and isoform has the potential to improve clinical practiceSankalita Ray Das, Brett Delahunt, Annette Lasham, et al.
Molecular Cancer Therapeutics|July 23, 2008
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repairMahmoud Toulany, Rainer Kehlbach, Urszula Florczak, et al.
Pageof 9